| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 4
Liposome encapsulated curcumin in lysine-collagen hydrogel embedded with valsartan for treatment of diabetic wounds
1 University of Lagos, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, PMB 12003, Lagos, NigeriaDOI : 10.23893/1307-2080.APS6252 Viewed : 410 - Downloaded : 138 Impaired wound healing occurs due to factors such as diabetes, resulting in slow healing. The aim of this study is to develop and evaluate the wound healing potential of curcumin encapsulated liposomes in a lysine-collagen-hydrogel matrix embedded with valsartan for diabetic wounds. Formulations, CF1 (curcumin encapsulated liposomes in lysine?collagen hydrogel), CF2 (curcumin encapsulated liposomes in lysine-collagen hydrogel embedded with valsartan), and CF3 (valsartan loaded lysine-collagen hydrogel) were prepared and evaluated for physicochemical, histological, histomorphometric and wound healing properties. Formulation CF2 had the highest swelling ratio which was 89.2 ± 1.95%, while CF3 had the highest viscosity of 60000.00 ± 2.07 m Pas. Formulation CF2 showed the best wound closure, which was 100% by day seven, followed by CF1, CF3, Control and then diabetic wounds that were not treated. Formulation CF2 was found to be the most effective in promoting re-epithelization and angiogenesis. It can serve as an effective formulation for the treatment of diabetic wounds. Keywords : liposome, hydrogel, wound healing, formulation, collagen